Cancer diagnostics company, Pacific Edge, has announced that test volumes remained steady in the fourth quarter of the financial year 2024.
The company processed 7,210 tests in the three months to the end of March, which was a 0.4% increase compared to the previous quarter.
In the United States, volumes rose to 6,099 tests, up 1.0% from the third quarter, while Asia Pacific volumes were down 2.7% to 1,111 tests.
Pacific Edge entered the fourth quarter with 16 full-time equivalent sales representatives, down from 21 in the previous quarter.
Test volumes for the 12 months ended March 2024 were up 3.4% to 32,633.
See more
